Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Humacyte Inc shares valued at $1,793,000 were sold by Dougan Brady W on Aug 19 ’25. At $1.63 per share, Dougan Brady W sold 1,100,000 shares. The insider’s holdings dropped to 591,685 shares worth approximately $1.04 million following the completion of this transaction.
Also, Dougan Brady W sold 549,360 shares, netting a total of over 1,005,329 in proceeds. Following the sale of shares at $1.83 each, the insider now holds 1,691,685 shares.
Before that, Dougan Brady W had sold 591,685 shares from its account. In a trade valued at $934,862, the Director traded Humacyte Inc shares for $1.58 each. Upon closing the transaction, the insider’s holdings decreased to 591,685 shares, worth approximately $0.0.
As published in their initiating research note from Barclays on August 27, 2025, Humacyte Inc [HUMA] has been an Overweight and the price target has been revised to $3.50. As of December 20, 2024, H.C. Wainwright has reiterated its “Buy” rating for HUMA. Earlier on December 11, 2023, H.C. Wainwright initiated its rating. Their recommendation was “a Buy” for HUMA stock.
Analyzing HUMA Stock Performance
On last trading session, Humacyte Inc [NASDAQ: HUMA] rose 1.15% to $1.76. The stock’s lowest price that day was $1.7, but it reached a high of $1.795 in the same session. During the last five days, there has been a surge of approximately 4.76%. Over the course of the year, Humacyte Inc shares have dropped approximately -68.46%. Shares of the company reached a 52-week high of $5.4800 on 01/02/25 and a 52-week low of $1.1500 on 04/08/25.
Support And Resistance Levels for Humacyte Inc (HUMA)
According to the 24-hour chart, there is a support level at 1.7083, which, if violated, would cause prices to drop to 1.6567. In the upper region, resistance lies at 1.8033. The next price resistance is at 1.8467. RSI (Relative Strength Index) is 54.20 on the 14-day chart, showing neutral technical sentiment.
Is Humacyte Inc subject to short interest?
Stocks of Humacyte Inc saw a sharp rise in short interest on 2025-09-15 jumping by 0.1 million shares to 34.36 million. Data from Yahoo Finance shows that the short interest on 2025-08-15 was 34.25 million shares. A jump of 0.31% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 10.19 of the overall float, the days-to-cover ratio (short ratio) jumped to 10.19.
Which companies own the most shares of Humacyte Inc (HUMA)?
In terms of Humacyte Inc share price expectations, FactSet research, analysts set an average price target of 3.5 in the next 12 months, up nearly 101.15% from the previous closing price of $1.74. Analysts anticipate Humacyte Inc stock to reach 3.5 by 2025, with the lowest price target being 3.5. In spite of this, 2 analysts ranked Humacyte Inc stock as Buy at the end of 2025. On August 14, 2023, Piper Sandler assigned a price target of “a Neutral” to the stock and upgraded coverage with a $3.50.
